ReviewProtein science : a publication of the Protein Society2026
Biophysical assessment of the molecular mechanisms of Tau aggregation and its role in Alzheimer's disease.
Review in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- 0N4R Tau aggregates producing morphologically different and structurally similar "on-path" and "off-path" oligomers.Chemical communications (Cambridge, England) · 2026Article
- Biophysical assessment of the molecular mechanisms of Tau aggregation and its role in Alzheimer's disease.Protein science : a publication of the Protein Society · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is characterized by the intracellular aggregation of the microtubule-associated protein Tau. While the presence of large, insoluble neurofibrillary tangles has long been the primary focus of this research, a paradigm shift in the field now highlights smaller, soluble oligomers as the more neurotoxic Tau species leading to neuronal death and cognitive decline. This leaves the important and ill-understood question of what molecular events lead to the conversion of healthy, functional Tau into these toxic oligomers. This review addresses the knowledge gap by investigating existing literature on the upstream mechanisms responsible for the onset of neurodegeneration and connecting it to disease pathogenesis. By synthesizing evidence from molecular biophysics, cellular biology, and neuropathology, this review summarizes the most recent understanding of factors contributing to pathological Tau aggregation, including post-translational modifications, lipids, and metal ions, among others. This review also discusses how neurotoxic Tau aggregates contribute to the onset of AD. By connecting these factors with findings from mammalian brain studies, this review establishes a comprehensive timeline of pathology that demystifies the transition from physiological Tau to toxic oligomers and links specific molecular triggers to the onset of neurodegeneration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.